Zymeworks (NASDAQ:ZYME) vs. CollPlant Biotechnologies (NASDAQ:CLGN) Critical Comparison

Zymeworks (NASDAQ:ZYME – Get Free Report) and CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 37.7% of Zymeworks shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Zymeworks and CollPlant Biotechnologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks 1 1 12 0 2.79
CollPlant Biotechnologies 1 1 0 0 1.50

Zymeworks presently has a consensus target price of $43.25, suggesting a potential upside of 65.46%. CollPlant Biotechnologies has a consensus target price of $120.00, suggesting a potential upside of 2,486.21%. Given CollPlant Biotechnologies’ higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Zymeworks.

Earnings and Valuation

This table compares Zymeworks and CollPlant Biotechnologies”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zymeworks $105.96 million 17.03 -$81.13 million $0.52 50.27
CollPlant Biotechnologies $318,000.00 27.59 -$11.49 million ($13.59) -0.34

CollPlant Biotechnologies has lower revenue, but higher earnings than Zymeworks. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zymeworks and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zymeworks 16.10% 22.23% 7.14%
CollPlant Biotechnologies -678.37% -298.21% -167.83%

Volatility & Risk

Zymeworks has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Summary

Zymeworks beats CollPlant Biotechnologies on 10 of the 14 factors compared between the two stocks.

About Zymeworks

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

About CollPlant Biotechnologies

(Get Free Report)

CollPlant Biotechnologies is an Israel-based regenerative medicine company developing products and technologies based on recombinant human collagen (rhCollagen). Its proprietary production process uses genetically engineered plants to produce human collagen, offering an alternative to collagen sourced from animals or human tissue. The company’s rhCollagen platform is intended for applications including tissue repair, 3D bioprinting and medical aesthetics. Its development work includes bioinks and other collagen-based materials designed for use in regenerative medicine and tissue engineering.

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.